UPDATE 3-Amgen again raises 2016 forecast in screen of confidence

An Amgen indication is seen at the company’s office in South San Francisco, California in this October 21, 2013 file photo.

Reuters/Robert Galbraith/Files

<articleLocation” > Amgen Inc (AMGN.O) on Wednesday published higher-than-expected second-quarter revenue on strong drug sales and once again raised its full-year projection in a clear signal of management confidence in business. The business is on track to satisfy or surpass its long-lasting goals, Chief Executive Robert Bradway said in a statement. Amgen, the world’s largest biotechnology company by market price, now expects 2016 adjusted profits of $11.10 to $11.40 per share, up from its previous view of $10.85 to $11.20. Its midpoint is above of Wall Street price quotes of $11.18 for the year. The company, which significantly increased its profits projection in April, likewise raised its full-year revenue outlook and now expects $22.5 billion to $22.8 billion, up from $22.2 billion to $22.6 billion. Excluding items, Amgen had changed revenues of $2.84 per share, topping experts’ typical expectations by 10 cents, according to Thomson Reuters I/B/E/ S.

” It’s consistent with the exceptional efficiency they have actually been having,” Cowen and Co expert Eric Schmidt said in a telephone interview. “Amgen’s had a really strong 5 of six quarters now.” Profits rose 6 percent to $5.7 billion, going beyond Wall Street estimates of about $5.6 billion, led by Enbrel, whose sales increased 10 percent to $1.48 billion, helped by rate boosts.

On a teleconference with analysts, Amgen Chief Financial Officer David Meline said the business was taking a look at a number of intriguing potential customers for prospective deals on brand-new drugs that could close this year. “We remain in a financial position to be competitive,” he stated. Amgen stated net profit rose to $1.87 billion, or $2.47 per share, from $1.65 billion, or $2.15 per share, a year back. Sales of the osteoporosis drug Prolia rose 30 percent to $441 million, sailing past Wall Street estimates of about $388 million. Sales of the numerous myeloma drug Kyprolis leapt 45 percent to $172 million, shy of experts’ agreement forecast of about $185 million.

Sales of Amgen’s potent, pricey brand-new cholesterol fighter Repatha remained anemic at simply $27 million, mainly held back by insurers choosing not to cover the medication for many clients. The company is expecting information on Repatha later on this year and in early 2017 that might encourage more reimbursement by insurance companies if results show that it reverses plaque buildup in arteries and avoids cardiac arrest and deaths. Repatha was approved on its ability to significantly lower “bad” LDL cholesterol. (Reporting by Costs Berkrot; Editing by Richard Chang).

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *